p30/PSA and RSID-Semen

Prostate-specific antigen was characterised in forensic serology before its clinical utility in oncology was established. In 1978 George Sensabaugh at the University of California, Berkeley, described a 30-kilodalton protein in seminal plasma that could be used to identify semen stains. He called it p30, after its approximate molecular weight on SDS-PAGE gels. It was not until 1986 that the US Food and Drug Administration approved PSA as a clinical serum marker, and the cross-identification of Sensabaugh's p30 as the same molecule as clinical PSA confirmed that forensic serologists had been detecting prostate-specific antigen for over a decade before the oncology community elevated it to prominence.

The biological basis of its forensic utility is the enormous concentration difference between seminal plasma and all other body fluids. Seminal plasma PSA runs at 0.5 to 2 mg/mL. Male blood serum PSA is in the range of 0.1 to 4 ng/mL in a healthy man. The forensic assay is working at the ng/mL level on diluted stain extracts, which corresponds to seminal plasma diluted millions of times, yet still returns a positive result. This is why PSA-based lateral-flow cards work on items that were washed or that carry only a trace of a stain.

The standard PSA test format for forensic use is the lateral-flow immunochromatographic strip. A coloured antibody-conjugate pad at one end of a nitrocellulose membrane is reconstituted with the sample extract; as the liquid front migrates up the membrane, target antigen in the extract is captured by a test-line antibody and forms a visible coloured band. A control line confirms the strip functioned.

The ABAcard is the dominant format in North American laboratories. Its sensitivity (limit of detection approximately 0.2-4 ng/mL depending on lot and extraction volume) is well above the concentrations expected from female paraurethral PSA in a vaginal swab taken in the absence of semen. The Seratec PSA Semiquant is more common in European labs and adds the ability to estimate concentration tier by comparing band intensity to the reference line, which some examiners use to assess whether a low-positive result is consistent with diluted semen versus a female-source background.

RSID-Semen (Rapid Stain Identification) was developed by Independent Forensics (Lombard, Illinois) and introduced to forensic practice in the mid-2000s. Its target is semenogelin I and II, proteins produced by the seminal vesicles. Because the seminal vesicles are anatomically and biochemically distinct from the prostate, RSID-Semen and PSA tests report on different biological sources of protein within semen. A stain can be RSID-positive and PSA-positive, or one can be positive while the other has degraded below threshold, which is valuable in aged samples.

The format is a single-use immunochromatographic strip run the same way as the PSA cards. Published validation data show sensitivity in the range of 1:10,000 to 1:100,000 dilution of fresh semen, with positive results on stains aged up to several years under laboratory storage conditions. A validation study by Hartman et al. (2011, published in the Journal of Forensic Sciences) showed RSID-Semen maintained positivity on stained fabrics stored at room temperature for up to 10 years, outperforming some PSA lateral-flow cards on the oldest samples.

A recurring casework question is how long a stain can age before PSA or RSID-Semen tests return a negative result when semen was genuinely deposited. Published data give the following picture, which should be treated as a guide rather than a hard cut-off because storage conditions (temperature, humidity, UV exposure) vary enormously between real cases.

The practical implication is that a DNA-aged cold-case item often returns positive RSID-Semen results long after sperm microscopy and even PSA tests have gone negative. This is why a complete semen identification battery runs all three: AP screen for triage, PSA for confirmation, RSID for independent confirmation and aged-sample backup. Each adds evidence with a different degradation profile.

A vasectomy severs the vas deferens, preventing sperm from reaching the urethra during ejaculation. It does not affect the prostate or the seminal vesicles, which are the source organs for PSA and semenogelin respectively. Post-vasectomy ejaculate therefore contains both proteins at concentrations that are generally normal or near-normal. Both PSA lateral-flow cards and RSID-Semen will test positive on ejaculate from a successfully vasectomised man.

Non-obstructive azoospermia (the failure to produce sperm due to testicular dysfunction) also does not affect prostatic or seminal vesicle secretion. A man with non-obstructive azoospermia has normal or near-normal seminal plasma protein concentrations with zero spermatozoa. His ejaculate tests AP-positive, PSA-positive, RSID-positive, and sperm-negative on microscopy. This combination is the clearest demonstration that the protein tests are confirming semen (the fluid) rather than just confirming spermatozoa (the cells).

The pattern across these donor categories is the argument for running both a sperm search and a protein test on every item. The protein tests catch cases the microscopy misses; the microscopy catches degraded samples where proteins have washed out but ghost heads remain. The two approaches are complementary because they detect different biological components of the same ejaculate.

No single test confirms semen in isolation. Each test has a sensitivity floor below which it cannot detect, and each has rare false-positive or false-negative scenarios. The standard practice in accredited forensic laboratories is to apply multiple tests to a positive screen result, interpret them as a battery, and report the combined strength of the identification.

• AP positive + PSA positive + sperm present: strong, multi-test confirmation. Report as semen identified.
• AP positive + PSA positive + sperm absent: semen confirmed; donor may be azoospermic or sperm degraded. Report as semen identified, sperm not found.
• AP positive + PSA negative + RSID positive: semen confirmed by RSID. PSA may have degraded or be below threshold. Report as semen identified by RSID; PSA not detected.
• AP positive + PSA negative + RSID negative: AP is unconfirmed as semen; likely a non-semen AP source. Report as no semen identified; AP screen positive due to possible non-semen source.
• AP negative + sperm present: rare scenario where AP has degraded but cell morphology survives. Sperm finding alone confirms semen. AP result does not negate the microscopy finding.

Reporting language matters. 'Semen detected' or 'semen identified' should be reserved for cases where a semen-specific confirmatory test (not just AP) is positive. 'Consistent with semen' or 'presumptive positive for semen' is appropriate for an AP-only positive. The distinction affects how the result is interpreted in court.

Lateral-flow cards give a qualitative or semi-quantitative result. In some casework scenarios, a quantitative PSA value by ELISA is warranted: when a borderline lateral-flow result must be distinguished from female-background PSA; when a case involves a suspected mixture and relative contributions are at issue; or when PSA concentrations across multiple items from the same case must be compared.

Standard clinical ELISA kits originally designed for oncology PSA measurement are used in forensic laboratories after internal validation. The extract is run at multiple dilutions against a calibration curve. A result above the laboratory's validated threshold (commonly 0.5 ng/mL or higher) in a stain extract from a sexual assault item is interpreted as semen-positive. Below-threshold results are reported as PSA not detected at this threshold, not as semen-negative, to avoid overstating a negative conclusion.